Post by Medtronic Structural Heart

The SMART Trial returns with 3-year results. Presented at EuroPCR 2026, these findings add an important layer to how we think about valve performance in TAVR. Explore the full results: https://lnkd.in/edw4zjYt (Bioprosthetic valve dysfunction at three years: Evolut TAVR 16.3%, SAPIEN TAVR 54.4%, p<0.001). TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. Important safety information: https://lnkd.in/epDuZTeV